Document is current
Any future updates will be listed below
-
Authors
Bower, Oliver J.
R. Orsi, Ana E. https://orcid.org/0000-0002-4939-1423
McMahon, Riley
Staneva, Desislava https://orcid.org/0000-0003-1330-2158
Blagrove, Josephine R. https://orcid.org/0000-0003-2765-3514
Singh, Kashish https://orcid.org/0000-0002-9891-8148
Simon, Claire S. https://orcid.org/0000-0001-9614-1403
McCarthy, Afshan
Garcia, Patricia https://orcid.org/0009-0009-9499-9401
Shaikly, Valerie
Taranissi, Mohamed
Wilding, Martin https://orcid.org/0000-0003-1829-6850
Serhal, Paul
Odia, Rabi A.
Vasilic, Mina
Choudhary, Meenakshi
Papathanasiou, Athanasios
Elder, Kay https://orcid.org/0000-0003-3510-8268
Snell, Phil
Christie, Leila
Arbab, Mandana
Liu, David R.
Herbert, Mary
Harasimov, Katarina https://orcid.org/0000-0003-2703-4342
Niakan, Kathy K. https://orcid.org/0000-0003-1646-4734
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 10 June 2026
First Online: 25 June 2026
Ethics
Competing interests: D.R.L. is a co-founder of Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants and nChroma Bio, companies that use or deliver genome editing agents, and a co-inventor on gene editing patents including foundational base editing and prime editing patents. After completing his PhD and his role in the project, O.J.B. became an employee of Preventive PBC, a public benefit corporation investigating the safety of gene editing technologies. The other authors declare no competing interests.
